Drug intelligence / Profile preview

DW-3101

Development stage: Unknown
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

DW-3101 is an investigational botanical drug candidate developed by Daewon Pharmaceutical for the treatment of acute and chronic gastritis. The drug consists of a standardized extract of *Opuntia ficus-indica*, commonly known as prickly pear cactus. It is designed to protect the gastric mucosa and reduce inflammation in patients with gastric erosions. DW-3101 has been evaluated in a Phase 2a multicenter, randomized, double-blind clinical trial in South Korea to determine its safety and optimal therapeutic dosage (150 mg, 300 mg, or 600 mg) compared to placebo.

Other names: Opuntia ficus-indica extractPrickly pear cactus extract

Beyond the preview

Go deeper on DW-3101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-3101.

Explore the full profile